PhaseBio Pharmaceuticals Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending September 29, 2021 was 43.93% (a 40.76% increase compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -73.68%
  • Annual Research and Development (R&D) Expenses Growth for 2020 was 105.31% (a 22.14% increase from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2019 was 86.22% (a -14.1% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2018 was 100.37% (a 263.92% increase from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending September 29, 2021 was 67.15% (a -16.03% decrease compared to previous quarter)
  • Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -49.59% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
67.15% 79.97% 126.42% 133.21%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of PhaseBio Pharmaceuticals

Most recent Research and Development (R&D) Expenses Growthof PHAS including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 43.93% 31.21% 94.95%
2020 166.88% 92.91% 168.04% 100.12% 105.31%
2019 47.66% 107.35% 143.92% 155.97% 86.22%
2018 326.77% 100.37%
2017 27.58%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.